Graybug seeks alternative options for eye drugs; RA-backed epilepsy outfit secures $40M Series C
Graybug Vision is in search of a new home about 21 months after landing on the Nasdaq. The ocular disease-focused biotech has seen its stock $GRAY plummet amid the biotech bear market, nosediving from a September 2020 listing at $16 to $1 territory the past few months.
The Baltimore company’s stock is rebounding Tuesday morning, though, thanks to an announcement before the opening bell that the gene therapy developer would seek a strategic alternative thanks to the help of financial advisor Piper Sandler.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.